Pancreatic Cancer Prevention Vaccine Shows 90% Success in Phase 1 — Can We Intercept Cancer Before It Starts?
One-line conclusion: Johns Hopkins University's mKRAS-VAX pancreatic cancer prevention vaccine showed a 90% immune response rate in Phase 1 trials — humanity's first attempt at intercepting cancer before it forms. Though the study only involved 20 people, subsequent Phase 2/3 trials will be crucial. The Hook: A New Weapon Against the "King of Cancers" Pancreatic cancer is known as the "King of Cancers"—with a five-year survival rate under 10%. Early symptoms are virtually nonexistent; by the time most patients are diagnosed, the disease has typically reached advanced stages. The traditional treatment model is "wait for cancer to develop, then treat." Johns Hopkins researchers propose a radically different approach: intercept the cancer before it even forms. Their novel vaccine, mKRAS-VAX, delivered breakthrough results in recently published Phase 1 clinical trial data—90% of participants developed strong T-cell immune responses, and t...